

RECEIVED
CENTRAL FAX CENTER

DEC. 7. 2006 2:23PM CALFEE HALTER GRISWOLD

DEC 07 2006 NO. 0337 P. 4

Customer Number

24024

CERTIFICATE OF FACSIMILE TRANSMITTAL

I hereby certify that this AMENDMENT is being
faxed to FAX NUMBER: 571-273-8300 on this 7th day of
December 7, 2006.

Attention: Dr. Saunders, David A.

Typed or Printed name of person signing this certificate:

Wendy A. Frick

Signed: Wendy A. Frick

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: Saunders, David A.
Hazen, et al.)	
Serial No.: 10/039,753)	Art Unit: 1644
Filed: January 2, 2002)	Confirmation No.: 9142
For: MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE)	Attorney Docket No.: 26473/04177

Do not enter DAB
Fax Number 571-273-8300
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

3/15/07

AMENDMENT AFTER FINAL

Dear Sir:

The following is responsive to the Final Office Action mailed November 22, 2006. Please amend the above-described application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 10 of this paper.

Customer Number

24024

CERTIFICATE OF ELECTRONIC FILING

I hereby certify that this document is being transmitted electronically via the United States Patent and Trademark Office's Electronic Filing Service (EFS-Web) on this 3rd day of January, 2007.

Wendy A. Frick
Wendy A. Frick

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: Saunders, David A.
Hazen, et al.)	
)	
Serial No.: 10/039,753)	Art Unit: 1644
)	
Filed: January 2, 2002)	Confirmation No.: 9142
)	
For: MYELOPEROXIDASE, A RISK INDICATOR FOR CARDIOVASCULAR DISEASE)	Attorney Docket No.: 26473/04177
)	

OK to enter
dtl
3/15/07
Fax Number 571-273-8300
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

AMENDMENT AFTER FINAL and
RESPONSE TO ADVISORY ACTION

Dear Sir:

The following is responsive to the Final Office Action mailed November 22, 2006 and the Advisory Action mailed December 28, 2006. Please amend the above-described application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks begin on page 10 of this paper.

FEB. 28. 2007 3:37PM CALFEE HALTER GRISWOLD

NO. 4060 P. 3
Customer Number

24024

RECEIVED
CENTRAL FAX CENTER

FEB 28 2007

CERTIFICATE OF FACSIMILE TRANSMITTAL
I hereby certify that this Response to Second Advisory Action is being
faxed to FAX NUMBER: 571-273-8300 on this 28th day of
February, 2007.

Attention: Dr. Saunders, David A.
Typed or Printed name of person signing this certificate:
Patricia Lewis

Signed: Patricia Lewis

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Hazen, et al.

)
Examiner: Saunders, David A.

Serial No.: 10/039,753

)
Art Unit: 1644

Filed: January 2, 2002

)
Confirmation No.: 9142

For: MYELOPEROXIDASE,
A RISK INDICATOR FOR
CARDIOVASCULAR DISEASE

)
Attorney Docket No.: 26473/04177

*OK to
enter
DAS
3/15/07.*
Fax Number 571-273-8300
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RESPONSE TO SECOND ADVISORY ACTION

Dear Sir:

The following is responsive to the Second Advisory Action mailed February 21, 2007. Please amend the above-described application as follows:

There are no amendments to the specification.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 9 of this paper.